<DOC>
	<DOC>NCT01727154</DOC>
	<brief_summary>The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).</brief_summary>
	<brief_title>Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T</brief_title>
	<detailed_description>Subjects will receive sipuleucel-T, and potentially other medications, as part of the clinical trial in which they are concurrently enrolled. For this study, cellular and humoral immune responses will be assessed. No additional study treatments will be conducted beyond what is required for the subject's concurrent clinical trial.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Subjects must be at least 18 years of age Subjects with prostate cancer who are enrolled in a clinical trial of sipuleucelT (including a Dendreonsponsored clinical trial or registry, or an IIT) Subjects have not yet undergone leukapheresis for their first dose of sipuleucelT Subjects must understand and sign an informed consent form prior to their first leukapheresis •None</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>